✦ LIBER ✦

Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B

✍ Scribed by Michiko Shindo; Tadao Okuno; Masayuki Matsumoto; Makoto Takeda; Tatsuro Takino; Junko Sokawa; Akira Iwata; Yoshihiro Sokawa

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 461 KB
Volume: 8
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840080229

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum levels of 2′, 5 oligoadenylate syn

Serum levels of 2′, 5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia

✍ Dr. C. Musolino; P. Grosso; A. Alonci; A. Allegra; A. Orlando; M. Cincotta; G. B 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB 👁 2 views

Effect of interferon treatment on serum

Effect of interferon treatment on serum 2′,5′-oligoadenylate synthetase levels in hepatitis C-infected patients

✍ Shiro Murashima; Ryukichi Kumashiro; Tatsuya Ide; Ichiro Miyajima; Teruko Hino; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 2 views

Elevated levels of 2′,5′-oligoadenylate

Elevated levels of 2′,5′-oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during acute exacerbation of chronic hepatitis B

✍ Michiko Shindo; Tadao Okuno; Ken Arai; Masayuki Matsumoto; Makoto Takeda; Tatsur 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 496 KB

Interferon treatment of chronic active h

Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia

✍ Waldron, Peter 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 2 views

Due to concerns that antineoplastic therapy produces prolonged decrease in immune function, interferon treatment of chronic active hepatitis C (CAHC) has been used only at one year or longer after the end of cancer therapy. We report the experience of an 11-year-old who developed symptomatic CAHC at

Analysis of hepatitis B virus genotypes

Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B

✍ Zhang, Xinxin; Zoulim, Fabien; Habersetzer, François; Xiong, Sidong; Trépo, Chri 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 891 KB

The clinical importance of hepatitis B virus (HBV) genome variability has been reported recently. One example is the occurrence of hepatitis B virus pre-core mutants, which arise during spontaneous or interferon-induced seroconversion from HBeAg to anti-HBe and are thought to be selected by immune p

Patterns of viral decline during PEG-int

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

✍ Martijn J. ter Borg; Monika van Zonneveld; Stefan Zeuzem; Hakan Senturk; Ulus S. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 423 KB 👁 2 views

In chronic hepatitis B, it is difficult to predict an early therapeutic response. We investigated the viral decline during therapy with pegylated interferon alpha-2b (PEG-IFN) with or without lamivudine in 266 HBeAg-positive chronic hepatitis B patients. In patients treated with PEG-IFN and lamivudi